Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Aqua Bio Technology Earnings Release 2015

Feb 10, 2016

3535_rns_2016-02-10_8a330289-921d-431c-942f-2296589e96b5.html

Earnings Release

Open in viewer

Opens in your device viewer

Aqua Bio Technology reports best fiscal year in company history for 2015

Aqua Bio Technology reports best fiscal year in company history for 2015

Aqua Bio Technology ASA today announced its preliminary financial results for

2015. A strong fourth quarter contributed to the Company's best fiscal year in

company history. Sales, financial results and cash position reached all time

high levels in 2015.

ABT's income for 2015 ended at NOK 38.9 million after a 73 percent revenue

growth from the 2014 income of NOK 22.5 million. The revenue growth in the

fourth quarter alone was 79 percent. The income development was in line with

expectations, based on contracts with ABT's U.S. based exclusivity partners.

EBITDA for 2015 ended at NOK 21.2 million, compared to NOK 5.8 million the

previous year. The 2015 EBITDA corresponds to a margin of 55 percent. For the

fourth quarter alone, the EBITDA margin was 61 percent. The Company's net result

for 2015 came in at NOK 15.0 million, against NOK 0.9 million the previous year.

Aqua Bio Technology improved its cash holdings even further in the fourth

quarter, and enjoyed a strong cash position of NOK 42 million at year-end.

Based on the Company's strong cash position and profits, following an approved

audit of the 2015 financial results, it is the intention of the Board of

Directors to recommend a dividend of NOK 1,50 per share to its General Assembly.

"Our financial flexibility in combination with our core expertise, which is the

commercialization of new bio technology, enables us to pursue a strategy of

expansion," said CEO Arvid Lindberg.

ABT has in 2015 assessed a number of biotechnology projects and companies in its

search for additional commercial partners. Moving into 2016, ABT forecasts a

number of technology in-licensing partnerships in the near future.

"Through building a broader technology base, we will expand ABTs business model

and value creation potential going forward," Arvid Lindberg said.

For further information, please call Arvid Lindberg, CEO, telephone

+47 9824 5410

Aqua Bio Technology (ABT) has launched several cosmetic ingredients used in skin

care products globally. The ingredient, based on the Company's unique, marine

technology and other technologies, have documented positive effects on the skin.

Skin care is the fastest growing segment in the cosmetics industry, where ABT's

ingredients have established a foothold. In addition to ingredients from its own

technology, ABT also commercializes technologies/ingredients for partners, for

use in novel skin care products. Aqua Bio Technology is listed on the Axess

market of the Oslo Stock Exchange.

This information is subject to the disclosure requirements pursuant to section

5-12 of the Norwegian Securities Trading Act.

[HUG#1984907]